Mrs. Rukmini Zainal Abidin, opened the first nationally indigenous owned pharmacy.
Mr. Zainal Abidin, opened his first indigenous pharmaceutical factory, PT ABDI.
Mrs Rukmini and Mr. Zainal Abidin opened their second factory,
PT TUNGGAL, and began a period of long-standing collaboration with various pharmaceutical multinational companies as their appointed toll manufacturer.
PT TUNGGAL, began a 30 year collaboration with Upjohn Co. in producing DepoProvera on behalf of Pfizer for the Indonesian market, where Tunggal produced over 120 million vials during this period.
PT TUNGGAL IDAMAN ABDI jointly with Concept Foundation, participated in a global study, and became the licensee manufacturer of the innovator monthly injectable contraceptive, Cyclofem.
The merger of PT TUNGGAL and
PT ABDI was established and officially became
PT TUNGGAL IDAMAN ABDI
PT TUNGGAL IDAMAN ABDI revamped its hormone injectable line, installing its first Bosch compact filling machine.
PT TUNGGAL IDAMAN ABDI, launched its own three monthly injectable, Triclofem.
PT TUNGGAL IDAMAN ABDI launched its herbal range, Herbatia, consisting of standardised herbal extracts for both post and pre natal treatments.
PT TUNGGAL IDAMAN ABDI officially began operating its new dedicated hormone plant, and filed its submission for WHO Pre-Qualification on its three-monthly injectable contraceptives.
PT TUNGGAL IDAMAN ABDI launched its medical device range, Femitia, offering a range of medical devices aimed for the midwives, such as medical gloves, pregnancy test kit, and syringes.
PT TUNGGAL IDAMAN ABDI opened its 45th domestic branch in Jayapura, where we are now present in 31 major cities nationally, serving over 46,000 midwives and all major healthcare outlets throughout Indonesia.
PT TUNGGAL IDAMAN ABDI was awarded an Expert Review Panel certification (ERP) by UNFPA which made Triclofem eligible for procurement by WHO related agencies and major NGOs.
Celebrating its 50th year anniversary,
PT TUNGGAL IDAMAN ABDI’s combined export of its monthly and three monthly injectables today stretches to over 50 countries in Asia, Africa and South America.